Acute Myeloid Leukemia: Role of FLT3 Inhibitors After Allogeneic Hematopoietic Cell Transplantation
It is important for clinicians to be aware of the emerging evidence supporting the use of FLT3 inhibitors as a predictor of post-transplant relapse in patients with AML.
Category
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation